Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO

BACKGROUND: Immune checkpoint inhibitors (ICIs) with or without chemotherapy represent first-line standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. The most appropriate second-line therapy after failing immunochemotherapy remains an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Grohé, Christian, Wehler, Thomas, Dechow, Tobias, Henschke, Sven, Schuette, Wolfgang, Dittrich, Ina, Hammerschmidt, Stefan, Müller-Huesmann, Harald, Schumann, Christian, Krüger, Stefan, Atz, Judith, Kaiser, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641040/
https://www.ncbi.nlm.nih.gov/pubmed/36386456
http://dx.doi.org/10.21037/tlcr-21-1018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641040/
https://www.ncbi.nlm.nih.gov/pubmed/36386456
http://dx.doi.org/10.21037/tlcr-21-1018

Ejemplares similares